Benchmark Maintains Speculative Buy on Seelos Therapeutics, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson maintains a Speculative Buy on Seelos Therapeutics (NASDAQ:SEEL), but lowers the price target from $4 to $1.
September 21, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Seelos Therapeutics' price target has been lowered from $4 to $1 by Benchmark, though the Speculative Buy rating is maintained.
The lowering of the price target by Benchmark indicates a potential decrease in the stock's value. However, the maintenance of the Speculative Buy rating suggests that the stock may still have potential upside, albeit at a lower price point.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100